Marchetti Alessio, Garnier Jonathan, Habib Joseph R, Rompen Ingmar F, Andel Paul C M, Salinas Camila Hidalgo, Ratner Molly, De Pastena Matteo, Salvia Roberto, Hewitt D Brock, Morgan Katherine, Kluger Michael D, Garg Karan, Javed Ammar A, Wolfgang Christopher L, Sacks Greg D
Division of Hepatobiliary and Pancreatic Surgery, NYU Langone Health, NYU Grossman School of Medicine, New York, NY, USA.
General and Pancreatic Surgery Unit, Pancreas Institute, University of Verona, Verona, Italy.
Ann Surg Oncol. 2025 Jun 30. doi: 10.1245/s10434-025-17686-y.
Antithrombotic therapy (AT) aims to strike a balance between preventing thromboembolic and hemorrhagic complications. However, evidence for AT management after pancreatectomy with vascular reconstruction is lacking. We aimed to provide an overview of the current use of AT for pancreatic surgery with vascular reconstructions.
A web-based survey was distributed to 123 surgeons from high-volume pancreas centers (>50 pancreatic resections/year). AT management after different types of vascular reconstruction were investigated. An "aggressive" protocol was defined as the use of any AT protocol other than prophylactic heparin, aspirin, or their combination.
The survey was completed by 80 surgeons (59% Europe, 30% USA, 11% Asia). In Europe/Asia, prophylactic heparin was the most commonly reported protocol after partial venous resection/end-to-end anastomosis/human graft (71%/65%/50%, respectively), and an "aggressive" protocol (86%) was the most frequently used after prosthetic graft reconstruction. Conversely, in the USA, prophylactic heparin + aspirin was the most commonly reported protocol after all types of venous reconstruction. Following arterial reconstruction, heparin + aspirin was the most commonly reported protocol, regardless of region. An "aggressive" protocol was more frequently used in Europe/Asia (odds ratio (OR) 1.28; p < 0.001) and following vein reconstruction with either human graft (OR 1.2; p = 0.007) or prosthetic graft (OR 1.56, p <0.001), while ultrasound (OR 1.65; p < 0.001) and arterial reconstruction (OR 1.64; p < 0.001) were significantly associated with antiplatelet use.
In an international cohort of high-volume pancreas surgeons, significant variation in the use of AT following pancreatectomy with vascular reconstruction was observed. This variation was driven by geographical differences and the type of vascular reconstructions performed. In an international cohort of high-volume pancreas surgeons, this Worldwide Snapshot Survey analyzed the current use of antithrombotic therapy for pancreatic surgery with vascular reconstruction. A significant heterogeneity in antithrombotic practice was found and it was mainly driven by geographical differences and the type of vascular reconstructions performed.
抗栓治疗(AT)旨在在预防血栓栓塞并发症和出血并发症之间取得平衡。然而,胰腺切除联合血管重建术后抗栓治疗管理的证据尚缺乏。我们旨在概述目前在胰腺手术联合血管重建中抗栓治疗的应用情况。
向来自高容量胰腺中心(每年>50例胰腺切除术)的123名外科医生进行了基于网络的调查。调查了不同类型血管重建术后的抗栓治疗管理情况。“积极”方案定义为使用除预防性肝素、阿司匹林或其联合使用之外的任何抗栓方案。
80名外科医生完成了调查(59%来自欧洲,30%来自美国,11%来自亚洲)。在欧洲/亚洲,部分静脉切除/端端吻合/人工血管移植术后,预防性肝素是最常报告的方案(分别为71%/65%/50%),而在人工血管移植重建术后,“积极”方案(86%)是最常用的。相反,在美国,所有类型静脉重建术后,预防性肝素+阿司匹林是最常报告的方案。动脉重建术后,肝素+阿司匹林是最常报告的方案,无论地区如何。在欧洲/亚洲(优势比(OR)1.28;p<0.001)以及使用人工血管(OR 1.2;p=0.007)或人工血管移植进行静脉重建后(OR 1.56,p<0.001),更常使用“积极”方案,而超声检查(OR 1.65;p<0.001)和动脉重建(OR 1.64;p<0.001)与抗血小板药物的使用显著相关。
在一组国际高容量胰腺外科医生中,观察到胰腺切除联合血管重建术后抗栓治疗的使用存在显著差异。这种差异是由地理差异和所进行的血管重建类型驱动的。在一组国际高容量胰腺外科医生中,这项全球快照调查分析了目前在胰腺手术联合血管重建中抗栓治疗的应用情况。发现抗栓治疗实践存在显著异质性,主要由地理差异和所进行的血管重建类型驱动。